All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

JUMP trial: How do patients with MF and lower grade fibrosis benefit from ruxolitinib?

During the EHA2021 Virtual Congress, the MPN Hub spoke with Haifa Kathrin Al-Ali, University Hospital Halle (Saale), Halle, DE. We asked, How do patients with myelofibrosis (MF) and lower grade fibrosis benefit from ruxolitinib?

JUMP trial: How do patients with MF and lower grade fibrosis benefit from ruxolitinib?

In this video, Al-Ali discusses insights from the JUMP trial, evaluating the impact of ruxolitinib on low-grade bone marrow fibrosis. She touches upon the degree of fibrosis, time to diagnosis, survival and long-term outcomes, prognostic factors, and response rates.


Share:
More about...